Polyglutamic (PGA)-coated nanoparticles for electrostatic incorporation |
Cell-targeted DNA delivery to primary endothelial cells |
RGD peptide [84] |
|
T cell-targeted DNA delivery |
Anti-CD3e f(ab´)2 [35] |
|
Cell-targeted mRNA delivery to T cells and hematopoietic stem cells (HSCs) |
Anti-CD3, anti-CD8, and anti-CD105 [85] |
|
Macrophage-targeted mRNA delivery |
Mannose [86] |
Covalently incorporated in PBAE structure |
Targeted DNA delivery to APCs |
Mannose [82,100,103] |
|
Targeted mRNA delivery to APCs |
Oligopeptide [83] |
|
Improved mucus penetration and DNA transfection in the lungs |
PEG (5 kDa) [114] |
|
Improved in vivo transfection of nucleic acid-based adjuvant after IP administration |
PEG (2 kDa) [77] |
|
Shielding to enhance tissue diffusivity |
PEG [78] |
Ligand functionalized lipid incorporated via hydrophobic interactions |
Improved cellular internalization and DNA transfection, reduced toxicity, and increased DNA loading |
Cell-penetrating peptides (CPPs) mTAT, bPrPp, and MPG [115] |
|
Minimized toxicity for safe and effective mRNA transfection of dendritic cells (DCs) |
PEGylated lipid [65] |
|
Shielding to improve colloidal stability and prevent aggregation in serum for potent mRNA transfection after systemic administration |
PEGylated lipid [25,80,81,97,116] |
|
Steric stabilization |
Pluronic F-108 [92] |